Saadat Ansari, MD
Internal Medicine · Huntsville, ALNPI 1861420994
Payments from drug & device makers
Across 531 payments — averaging $4004.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.1M
- Novartis$585K
- AstraZeneca$313K
- Alnylam Pharmaceuticals Inc.$88K
- Shionogi Inc$11K
- Kowa Research Institute, Inc.$4K
- plus $7K from 28 others
What the payments were for
- Travel & lodging$1,64219%
- Food & beverage$7,04781%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 101 | $1,119,025 |
| Novartis | 16 | $584,692 |
| AstraZeneca | 31 | $312,758 |
| Alnylam Pharmaceuticals Inc. | 13 | $87,581 |
| Shionogi Inc | 2 | $10,612 |
| Kowa Research Institute, Inc. | 3 | $4,400 |
| Novo Nordisk | 193 | $1,644 |
| Astrazeneca UK Limited | 5 | $1,642 |
| Indivior Inc. | 22 | $652 |
| GSK | 38 | $546 |
| Lilly USA, LLC | 15 | $307 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $302 |
| Axsome Therapeutics, Inc. | 6 | $263 |
| Merck | 7 | $243 |
| Dexcom, Inc. | 10 | $202 |
| Pfizer | 11 | $170 |
| Braeburn Inc. | 7 | $161 |
| Idorsia Pharmaceuticals US Inc | 4 | $145 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $124 |
| Bayer | 6 | $115 |
| Alkermes, Inc. | 1 | $87 |
| Scilex Pharmaceuticals Inc. | 5 | $73 |
| Lundbeck LLC | 3 | $60 |
| Boehringer Ingelheim | 4 | $60 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Astellas Pharma US Inc | 2 | $42 |
| Abbott | 2 | $38 |
| Orexo US, Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Vivus LLC | 2 | $31 |
| Amgen | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,126,258 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $110,195 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 559 | $75,360 |
| JardianceEmpagliflozin | 60 | $75,338 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $66,328 |
| EliquisApixaban | 57 | $62,197 |
| FarxigaDapagliflozin Propanediol | 59 | $61,207 |
| Tresiba Flextouch U-200Insulin Degludec | 50 | $49,915 |
| RybelsusSemaglutide | 24 | $45,572 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 153 | $43,902 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 211 | $42,922 |
| TrulicityDulaglutide | 31 | $37,292 |
| VraylarCariprazine Hcl | 23 | $35,078 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 79 | $23,007 |
| MyrbetriqMirabegron | 28 | $18,951 |
| LinzessLinaclotide | 19 | $17,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta | $546 | $166,485460 claims |
| Novo NordiskOzempic, Rybelsus | $1,644 | $155,767105 claims |
| Boehringer IngelheimJardiance, Tradjenta | $60 | $92,89271 claims |
| PfizerEliquis, Abrysvo | $170 | $85,204136 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $312,758 | $75,33183 claims |
| AbbVieVraylar, Linzess | $1,119,025 | $52,63842 claims |
| Lilly USA, LLCTrulicity | $307 | $37,29231 claims |
| Astellas Pharma US IncMyrbetriq | $42 | $18,95128 claims |
| BayerKerendia | $115 | $16,20512 claims |
| MerckBelsomra, Januvia | $243 | $16,08835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Huntsville
- Tiffany Schwasinger-SchmidtHuntsville$787K
- John ClarkHuntsville$756K
- Palak ShahHuntsville$49K
- Joseph HastieHuntsville$44K
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.